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Neural tube defects in Switzerland from 2001 to 2007: are
periconceptual folic acid recommendations being followed?
Abstract
BACKGROUND: Neural tube defects (NTDs) are common congenital anomalies. Their aetiology is
complex, with both genetic and environmental factors implicated. The present study was performed to
analyse the birth prevalence of NTD in Switzerland from 2001 to 2007 and to identify possible risk
factors. METHODS: Diagnosed cases of NTD in all paediatric units in Switzerland and four prenatal
centres were reported to the Swiss Paediatric Surveillance Unit from January 2001 to December 2007.
Patient, mother, and NTD characteristics were assessed prospectively with a questionnaire. RESULTS:
Data of 140 newborns and foetuses with NTD were studied. The major group suffered from
myelomeningocele (70%), followed by anencephaly (16%) and encephalocele (14%). The prevalence of
NTD in live born children between 2001 and 2007 was 0.13 per thousand, corresponding to 9-10
affected newborns each year. About the same number of pregnancies was terminated annually. Correct
periconceptual folic acid supplementation was taken by 5% of the women. Remarkably, 39% of the
women with an affected pregnancy were not Swiss citizens - almost twice the proportion of foreigners
living in Switzerland. CONCLUSIONS: NTDs remain a frequent problem in Switzerland. Although
correct periconceptual folic acid supplementation is effective in reducing the prevalence of NTD,
women still do not follow these recommendations. Possible reasons are lack of awareness and
communication problems. Consequently, only a public health policy that includes folic acid fortification
of food is likely to result in significant prevention of NTD.
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Background: Neural tube defects (NTDs) are
common congenital anomalies. Their aetiology is
complex, with both genetic and environmental
factors implicated. The present study was per-
formed to analyse the birth prevalence of NTD in
Switzerland from 2001 to 2007 and to identify
possible risk factors. 
Methods: Diagnosed cases of NTD in all pae-
diatric units in Switzerland and four prenatal cen-
tres were reported to the Swiss Paediatric Surveil-
lance Unit from January 2001 to December 2007.
Patient, mother, and NTD characteristics were
assessed prospectively with a questionnaire. 
Results: Data of 140 newborns and foetuses
with NTD were studied. The major group suf-
fered from myelomeningocele (70%), followed by
anencephaly (16%) and encephalocele (14%).
The prevalence of NTD in live born children be-
tween 2001 and 2007 was 0.13‰, corresponding
to 9–10 affected newborns each year. About the
same number of pregnancies was terminated an-
nually. Correct periconceptual folic acid supple-
mentation was taken by 5% of the women. Re-
markably, 39% of the women with an affected
pregnancy were not Swiss citizens – almost twice
the proportion of foreigners living in Switzerland.
Conclusions: NTDs remain a frequent prob-
lem in Switzerland. Although correct periconcep-
tual folic acid supplementation is effective in re-
ducing the prevalence of NTD, women still do
not follow these recommendations. Possible rea-
sons are lack of awareness and communication
problems. Consequently, only a public health pol-
icy that includes folic acid fortification of food is
likely to result in significant prevention of NTD.
Key words: neural tube defects; myelomeningocele;
encephalocele; anencephaly; folic acid supplementation
Summary
Neural tube defects (NTDs) are common and
serious congenital malformations. About 1–2 per
1000 pregnancies are affected, both in the US and
in the European Union [1, 2]. The most frequent
open NTDs are myelomeningocele (MMC) [3]
and anencephaly [4]. MMC occurs due to the
failed closure of the caudal end of the neural tube,
which results in dysplasia of the spinal cord, nerve
roots, and meninges. Thereby MMC often leads
to irreversible neurological, urological, and or-
thopaedic impairments causing life-long disabili-
ties. Anencephaly results from a failed closure of
the rostral end of the neural tube. It is charac-
terised by a total or partial absence of the brain
and the overlying skull, and the outcome is always
lethal. However, encephalocele represents a post-
closure NTD. It is characterised by a membrane-
covered protrusion of the brain through an ab-
normal opening in the skull [5, 6]. The prognosis
of this defect is variable; syndromic forms are
often lethal. 
There is ample evidence that periconceptual
folic acid supplementation can significantly re-
duce the risk of NTD [7]. Consequently, health
organisations worldwide issue recommendations
for women to take 0.4 mg of synthetic folic acid
daily (4 mg daily to prevent NTD recurrence).
Supplementation is recommended starting at
least four weeks before conception continued
until the end of the first trimester. In Switzerland
these recommendations were formulated in 1996
and are currently supported by the Federal Office
of Public Health, the Swiss Nutrition Council,
the Swiss Paediatric Society, and the Swiss Society
of Gynaecology and Obstetrics [8]. Since 2000,
information on folic acid use has been widely
available to women of childbearing age. Due to a
lack of the necessary regulations, at present only
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voluntary fortification of food is allowed in
Switzerland. 
In 2001 the Swiss Paediatric Surveillance
Unit (SPSU) began a detailed analysis of the re-
ported cases of NTD in newborns. Additionally,
four foetal-maternal medicine centres were in-
cluded. The aim of the present study was to assess
NTD birth prevalence in Switzerland. Further
aims were to evaluate any trend in prenatally di-
agnosed NTD, possible risk factors, the impact of
periconceptual folic acid supplementation, and
pregnancy outcome with NTD. 
Methods
The period of NTD surveillance was from January 1
2001 to December 31 2007. Ours was a cross-sectional
observational study. Before the start of the surveillance,
all 38 paediatric and neonatal units in Switzerland re-
ceived information about the project as well as the study
protocol. All the information was ascertained with a ques-
tionnaire completed by physicians on a voluntary basis.
The mothers remained anonymous and could not be con-
tacted later. All the paediatric or neonatal units, which
were confronted with a NTD case, participated in the
study. To detect any trend in prenatally diagnosed NTD,
four foetal-maternal medicine centres (University Hospi-
tals at Basle, Geneva, and Zurich, and the centre in
Lucerne) were also included. It has been estimated that
these centres cover about 59% of the Swiss population
[9]. Hence we included all newborns with NTD and were
able to detect major trends in prenatal diagnosis. It was
not possible to include all prenatally diagnosed NTD, be-
cause at present a comprehensive surveillance system is
not available in Switzerland. 
Swiss Paediatric Surveillance Unit (SPSU)
The Swiss Paediatric Surveillance Unit (SPSU) was
established in 1995 to assess the epidemiological features
of selected childhood diseases leading to hospitalisation.
Monthly, hospitals report occurring cases of the respec-
tive disease to the SPSU. Consequently the treating
physician answers a questionnaire concerning the re-
ported anonymous case. On this basis no case control or
interventional studies are possible. The SPSU is operated
under the auspices of the Swiss Paediatric Society and the
Swiss Federal Office of Public Health. 
Case definition
The study population comprised newborns with
NTD admitted to all paediatric units in Switzerland. Foe-
tuses with NTD from four foetal-maternal medicine cen-
tres were also included. The main categories were MMC,
anencephaly (including acrania, craniorachischisis, and
exencephaly), and encephalocele. The data assessed in-
cluded year of diagnosis, sex of the foetus, type of NTD,
age and nationality of the mother, and folic acid supple-
mentation (periconceptual, postconceptual, or no supple-
mentation). Moreover the questionnaires addressed pre-
natal diagnosis, cases of recurrence, intake of possible ter-
atogenic drugs such as antiepileptic drugs during the
pregnancy, and outcome of the pregnancy (live birth, still
birth/spontaneous abortion, or termination of pregnancy
(TOP)). Folate receptor antibodies were analysed only in
one case, because this analysis was not part of the study
[10]. Supplementation is defined as periconceptual if
starting at least four weeks before conception and contin-
ued until the end of the first trimester. Extracranial mal-
formations were assessed with the aim of recognising pos-
sible syndromic NTD. 
We excluded newborns and foetuses with closed
spinal dysraphism, such as diastematomyelia, lipome -
ningocele, thickened filum terminale, caudal regression
syndrome, intradural lipoma, and dermal sinus. This cate-
gory of mainly caudal defects is probably independent of
folate and embryologically distinct from MMC [11].
Most of them are diagnosed late, sometimes even in
adulthood [12]. All cases with an unclear diagnosis, even if
reported as NTD, were not evaluated. 
Statistics 
The birth prevalence of NTD was calculated as the
total of newborns with NTD divided by the total number
of live births during the study period. The annual total
number of Swiss births was obtained from the Swiss Fed-
eral Office of Statistics. This data base was also used as a
source for the number of foreigners living in Switzerland
and the Swiss population. 
Results 
During the study period, 140 foetuses and
newborns with NTD were identified. This corre-
sponds to an average of about 20 cases each year.
The distribution of NTD according to diagnostic
category and year is shown in fig. 1 and epidemio-
logical characteristics are listed in table 1. MMC
was the most frequently recorded anomaly with
98 cases (70% of all subjects). Anencephaly was
detected in 22 cases (16%) and encephalocele in
20 (14%). Sixty-seven of 140 foetuses were female
(48%) and 56 were male (40%), whereas in 17
TOP the gender was not identified (12%). An af-
fected sibling was reported in two families
(0.01%).
In 84 of 98 cases (86%) the MMC was iso-
lated, whereas in 14 cases (14%) MMC was part
of a syndrome such as trisomy 13 or 18. Nineteen
cases of anencephaly occurred in isolation (86%),
only three were syndromic (14%). Out of 20 en-
cephaloceles, eight cases were syndromic (40%).
Four of them represented part of the Meckel-
Gruber syndrome. 
The mean age of the mothers at the time of
delivery was 30 years (median 31, range 15–45
years). Eighty-two mothers were Swiss (59%) and
54 were foreigners (39%). In the remaining four
cases the nationality of the mothers was not re-
ported. Most foreign mothers originated from
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Southern Europe (n = 23, 43%), especially from
the Balkans (n = 19). 
NTD was diagnosed prenatally in 122 cases
(87%), whereas 16 cases (11%) were only de-
tected at birth. Eleven of those were MMCs and
five were encephaloceles. In two MMCs we do
not know whether they were diagnosed prena-
tally. However, all anencephalic foetuses were de-
tected prenatally by ultrasound. Twenty of the 22
pregnancies (91%) affected by anencephaly were
terminated following this diagnosis. However, the
TOP rate for encephalocele (73%) and MMC
(41%) was lower (fig. 2). Sixty-eight of 140 foe-
tuses were born alive (48%), corresponding to a
mean value of about 9–10 cases each year and to a
Swiss annual NTD birth prevalence of about
0.13‰. At birth, MMC was the most frequently
recorded NTD with 58 cases (85% of total new-
borns), whereas only nine were affected by en-
cephalocele (13%) and one by anencephaly (2%).
Anencephaly Myelomeningocele Encephalocele Total NTD
Total number 22 98 20 140
Sex* male 5 43 8 56
female 7 51 9 67
Age of the mothers median 
(years)** (range) 34 (21–45) 30 (15–37) 31.5 (19–43) 31 (15–45)
Nationality Swiss 11 60 11 82
of the mothers*** foreign 11 34 9 54
* In 17 cases of termination of pregnancies the sex was not specified
** In 6 cases the age of the mother was not specified
*** In 4 cases the nationaliy of the mother was not specified
Figure 1
Neural tube defects
according to diagnos-
tic category and year.
Table 1 
Epidemiological data
according to the neu-
ral tube defects 
(n = 140).
Figure 2 
Pregnancy outcome
of neural tube defects
after prenatal diagno-
sis according to cate-
gory.
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Two foetuses with MMC and one with anen-
cephaly were stillborn. Maternal periconceptual
folic acid supplementation was correct in only
seven cases (5%) (fig. 3). In one of these cases
NTD was reported as syndromic. Additionally, in
one case the pregnant woman received antiepilep-
tic therapy with valproic acid [13] and in another
case autoantibodies against folate receptors were
found subsequently in the maternal serum [10].
However, in 52 cases (37%) no folic acid supple-
mentation was taken and in nine cases it was only
taken postconceptionally (7%). In the majority of
cases (51%), information about folic acid supple-
mentation was not reported.
Figure 3 
Folic acid supplemen-
tation according to
year.
Discussion 
The NTD birth prevalence did not decline sub-
stantially during the past decade either in Europe [2,
14] or in Switzerland, as our study shows. A total of
140 NTD were reported to the SPSU from 2001 to
2007, corresponding to about 20 cases each year. Be-
cause almost 40% of them were born, the Swiss an-
nual NTD birth prevalence was about 0.13‰, which
signifies that 1–2 newborns in 10’000 births are af-
fected by NTD each year. Comparable published se-
ries in other countries as USA, UK, and Sweden show
a prevalence between 0.2–0.3‰ [15–17]. 
Prenatal diagnosis has improved during the last
30 years. In this report, the prenatal diagnosis rate
is 87% and corresponds to other published series,
which range from 82 to 98% [18, 19]. After the
prenatal diagnosis of NTD, about half of the preg-
nancies were terminated. In comparison to inter-
ruption rates of 60–83% published in similar stud-
ies, the rate in this analysis is lower [17, 20]. Only
four foetal-maternal centres were included, there-
fore a significant number of TOP was certainly
missed. Consequently, the percentage of born
MMC (59%) is above the ranges shown in the liter-
ature (20–52%) [20, 21]. 
The aetiology of NTD is complex and con-
sists of genetic and environmental factors. Embry-
onic genetic factors include chromosomal abnor-
malities such as trisomy 13 and 18 and syndromes
such as Meckel-Gruber. In our study, about 5% of
NTDs were associated with a syndrome, corre-
sponding to other published series (2–17%) [22].
Differentiation of syndromic NTD from isolated
forms is important in terms of pathogenesis, ge-
netic counseling, and prognosis. 
It is known that folate is important for regular
cell synthesis, especially when the cellular prolif-
eration rate is high such as during embryonal and
foetal growth [23]. The high density of folate car-
riers in the neural tube suggests a critical role for
folate during neural-tube closure around the 28th
day of pregnancy [24, 25]. Delivery of folate to the
embryo depends on maternal folate intake, ab-
sorption, metabolism, folate transport across the
placenta, and embryonal folate uptake [26]. Mu-
tated folate pathway genes such as methylenete-
trahydrofolate reductase (MTHFR) and folate re-
ceptor genes cause NTDs via both maternal and
embryonic genotypes [27, 28]. Possible environ-
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mental factors in the development of NTDs in-
clude low folic acid intake, autoantibodies against
the folate receptor, and drugs influencing the fo-
late metabolism such as valproic acid, as shown in
our study [10, 13, 29]. 
A low folate diet is the main factor in open,
non-syndromic NTD and can easily be influ-
enced. Therefore many health organisations have
recommended periconceptual supplementation
by 0.4 mg folic acid daily [2, 7]. Although consis-
tent supplementation reduces the risk of NTD by
40 to 80% [20, 30–32], a non-declining birth
prevalence of NTD is of concern to Switzerland
as well as to many other countries worldwide [2,
14]. This indicates that the recommendations
alone are not sufficiently effective. In fact, only
5% of the women in our study took folic acid in
the correct manner and half of the treating doc-
tors were not properly informed about the pa-
tients` intake of folic acid. The birth of a newborn
with an open NTD is very stressful for parents.
Therefore paediatricians obviously have a ten-
dency not to ask about folic acid supply in order
to avoid provoking feelings of guilt and self criti-
cism. Many women of childbearing age obviously
remain unaware of the need to take folic acid, es-
pecially because many pregnancies are unplanned
[2]. In Switzerland, this proportion is estimated
by the Swiss Society of Gynaecology and Obstet-
rics around 50%, which is comparable to French
data [33]. Youngsters, less educated individuals,
and immigrants are particularly vulnerable groups
[7]. Indeed, in our study the percentage of foreign
women bearing a pregnancy with NTD is two-
fold higher than the proportion of foreigners liv-
ing in Switzerland. This finding is important and
probably represents communication difficulties
both of treating doctors and public health cam-
paigns. Therefore, special attention should be
paid to language, cultural barriers, and also illiter-
acy [34]. However, despite public health cam-
paigns, ignorance of periconceptual folic acid
supplementation remains and only half of the
women of childbearing age follow the recommen-
dations [7]. The only way to address women at
risk might be through folic acid fortification of
food [35]. Among other strategies, this is already
performed in the USA and Canada and has im-
proved the folate status considerably [20, 36]. It
has thus led to a significant additional reduction
of the NTD prevalence by 20 to 50% [15, 21, 37].
We are aware of limitations in our study.
Firstly, only four prenatal centres (covering only
about 59% of the Swiss population) were in-
cluded, resulting in missing several aborted preg-
nancies (about one third to half). Secondly, many
report forms were only partially completed, espe-
cially regarding folic acid supplementation. This
limits the robustness of our conclusion, since
complete information is necessary for its confir-
mation and in understanding why periconceptual
folic acid recommendations are not being fol-
lowed. Thirdly, this study uses a descriptive ap-
proach limiting statistical analysis.
In summary, this study shows that the birth
prevalence of NTD in Switzerland has not signif-
icantly decreased over the last 7 years. NTD re-
mains a frequent congenital defect and a serious
medical and public health problem. Although the
protective role of periconceptual folic acid sup-
plementation is clear, women of childbearing age
still do not follow the recommendations. Possible
reasons are a lack of awareness and communica-
tion problems. Providing information on the ef-
fect of folic acid supplementation does not have
enough impact on the folic acid intake of women
at risk. Consequently, only a public health policy
that includes folic acid fortification of food is
likely to result in significant prevention of NTD.
We thank the SPSU representatives of the respective
paediatric and foetal-maternal medicine centres in
Switzerland (Ch. Aebi, E. Antonelli, W. Bär, V. Bernet, 
M. Bianchetti, M. Bittel, A. Blumberg, H. U. Bucher, 
L. Buetti, E. Bussmann, O. Carrel, P. O. Cattin, A. Cor-
boz, P. Diebold, P. Dolivo, F. Farron, M. Gehri, E. Gian-
noni, C. A. Haenggeli, M. Hodel, J. Hohlfeld, P. Hüppi, 
P. Imahorn, O. Irion, Ch. Kind, W. Kistler, B. Knöpfli, 
O. Lapaire, B. Laubscher, R. Leuthardt, U. Lips, 
A. Malzacher, J. Mayr, J. Mc Dougall, J.-L. Micheli, 
M. Mönkhoff, T. J. Neuhaus, V. Pezzoli, L. Reinhard, 
F. Renevey, H. Roten, Ch. Rudin, V. Schlumbom, 
M. Schwöbel, S. Sizonenko, S. Stocker, Ch. Stüssi, 
R. Tabin, P. Terrier, B. Wildhaber, J. Wildhaber, J. Wisser,
M. Wopmann, Z. Zachariou, G. Zeilinger, A. Zemmouri,
U. Zimmermann, H. Zimmermann, D. Beeli) for provid-
ing reports. 
Correspondence:
Prof. Dr. Eugen Boltshauser
Division of Paediatric Neurology
University Children’s Hospital
Steinwiesstrasse 75
CH-8032 Zurich
E-Mail: Eugen.Boltshauser@kispi.uzh.ch
608-613 Poretti 12352.qxp  8.10.2008  7:52 Uhr  Seite 612
613S W I S S  M E D  W K LY 2 0 0 8 ; 13 8 ( 4 1 – 4 2 ) : 6 0 8 – 6 13  ·  w w w. s m w. ch
References
1 Mulinare J, Erickson JD. Prevention of neural tube defects.
Teratology. 1997;56:17–8.
2 Busby A, Abramsky L, Dolk H, Armstrong B. Preventing neu-
ral tube defects in Europe: population based study. BMJ.
2005;330:574–5.
3 Mitchell LE, Adzick NS, Melchionne J, Pasquariello PS, 
Sutton LN, Whitehead AS. Spina bifida. Lancet. 2004;364:
1885–95.
4 Melnick M, Myrianthopoulos NC. Studies in neural tube de-
fects. II. Pathologic findings in a prospectively collected series
of anencephalics. Am J Med Genet. 1987;26:797–810.
5 Padmanabhan R. Etiology, pathogenesis and prevention of
neural tube defects. Congenital anomalies. 2006;46:55–67.
6 Rowland CA, Correa A, Cragan JD, Alverson CJ. Are en-
cephaloceles neural tube defects? Pediatrics. 2006;118:916–23.
7 Eichholzer M, Tonz O, Zimmermann R. Folic acid: a public-
health challenge. Lancet. 2006;367:1352–61.
8 Baerlocher K, Eichholzer M, Lüthy J, Moser U, Tönz O. Fol-
säure: Expertenbericht der Eidgenössischen Ernährungskom-
mission zur Prophylaxe von Neuralrohrdefekten. Edited by the
Federal Office of Public Health; 2002.
9 Tonz O. Kommentar zur Erfassung der Neuralrohrdefekte.
Paediatrica. 2002;13:84–5.
10 Rothenberg SP, da Costa MP, Sequeira JM, Cracco J, Roberts
JL, Weedon J, et al. Autoantibodies against folate receptors in
women with a pregnancy complicated by a neural-tube defect.
N Engl J Med. 2004,350:134–42.
11 Lemire RJ. Neural tube defects. JAMA. 1988;259:558–62.
12 Pacheco-Jacome E, Ballesteros MC, Jayakar P, Morrison G,
Ragheb J, Medina LS. Occult spinal dysraphism: evidence-
based diagnosis and treatment. Neuroimaging Clin N Am.
2003;13:327–34.
13 Yerby MS. Clinical care of pregnant women with epilepsy:
neural tube defects and folic acid supplementation. Epilepsia.
2003;44(Suppl 3):33–40.
14 Botto LD, Lisi A, Robert-Gnansia E, Erickson JD, Vollset SE,
Mastroiacovo P, et al. International retrospective cohort study
of neural tube defects in relation to folic acid recommenda-
tions: are the recommendations working? BMJ. 2005;330:571.
15 Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY.
Impact of folic acid fortification of the US food supply on the
occurrence of neural tube defects. JAMA. 2001;285:2981–6.
16 Nikkila A, Rydhstrom H, Kallen B. The incidence of spina bi-
fida in Sweden 1973–2003: the effect of prenatal diagnosis. Eur
J Public Health. 2006;16:660–2.
17 Morris JK, Wald NJ. Prevalence of neural tube defect pregnan-
cies in England and Wales from 1964 to 2004. J Med Screen.
2007;14:55–9.
18 Van Allen MI, Boyle E, Thiessen P, McFadden D, Cochrane D,
Chambers GK et al. The impact of prenatal diagnosis on neu-
ral tube defect (NTD) pregnancy versus birth incidence in
British Columbia. J Appl Genet. 2006;47:151–8.
19 Norem CT, Schoen EJ, Walton DL, Krieger RC, O’Keefe J, To
TT et al. Routine ultrasonography compared with maternal
serum alpha-fetoprotein for neural tube defect screening. Ob-
stet Gynecol. 2005;106:747–52.
20 De Wals P, Tairou F, Van Allen MI, Uh SH, Lowry RB, Sibbald
B et al. Reduction in neural-tube defects after folic acid fortifi-
cation in Canada. N Engl J Med. 2007;357:135–42.
21 Persad VL, Van den Hof MC, Dube JM, Zimmer P. Incidence
of open neural tube defects in Nova Scotia after folic acid for-
tification. CMAJ. 2002;167:241–5.
22 Lynch SA. Non-multifactorial neural tube defects. Am J Med
Genet. 2005;135:69–76.
23 Steegers-Theunissen RP. Folate metabolism and neural tube
defects: a review. Eur J Obstet Gynecol Reprod Biol. 1995;
61:39–48.
24 O’Rahilly R, Muller F. The two sites of fusion of the neural
folds and the two neuropores in the human embryo. Teratol-
ogy. 2002;65:162–70.
25 Maddox DM, Manlapat A, Roon P, Prasad P, Ganapathy V,
Smith SB. Reduced-folate carrier (RFC) is expressed in pla-
centa and yolk sac, as well as in cells of the developing fore-
brain, hindbrain, neural tube, craniofacial region, eye, limb
buds and heart. BMC Dev Biol. 2003;3:6.
26 Prasad PD, Ramamoorthy S, Moe AJ, Smith CH, Leibach FH,
Ganapathy V. Selective expression of the high-affinity isoform
of the folate receptor (FR-alpha) in the human placental syncy-
tiotrophoblast and choriocarcinoma cells. Biochim Biophys
Acta. 1994;1223:71–5.
27 De Marco P, Moroni A, Merello E, de Franchis R, Andreussi L,
Finnell RH et al. Folate pathway gene alterations in patients
with neural tube defects. Am J Med Genet. 2000;95:216–23.
28 Boyles AL, Hammock P, Speer MC. Candidate gene analysis in
human neural tube defects. Am J Med Genet. 2005;135:9–23.
29 Finnell RH, Gould A, Spiegelstein O. Pathobiology and genet-
ics of neural tube defects. Epilepsia. 2003;44(Suppl 3):14–23.
30 Czeizel AE, Dudas I. Prevention of the first occurrence of neu-
ral-tube defects by periconceptional vitamin supplementation.
N Engl J Med. 1992;327:1832–5.
31 Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H et al.
Prevention of neural-tube defects with folic acid in China.
China-U.S. Collaborative Project for Neural Tube Defect Pre-
vention. N Engl J Med. 1999;341:1485–90.
32 Lumley J, Watson L, Watson M, Bower C. Periconceptional
supplementation with folate and/or multivitamins for prevent-
ing neural tube defects. Cochrane Database Syst Rev. 2001;
3:CD001056.
33 Stoll C, Alembik Y, Dott B. Are the recommendations on the
prevention of neural tube defects working? Eur J Med Genet.
2006;49:461–5.
34 Ray JG, Singh G, Burrows RF. Evidence for suboptimal use of
periconceptional folic acid supplements globally. BJOG. 2004;
111:399–408.
35 Knudsen VK, Orozova-Bekkevold I, Rasmussen LB,
Mikkelsen TB, Michaelsen KF, Olsen SF. Low compliance
with recommendations on folic acid use in relation to preg-
nancy: is there a need for fortification? Public Health Nutr.
2004;7:843–50.
36 Rader JI. Folic acid fortification, folate status and plasma ho-
mocysteine. J Nutr. 2002;132:2466S–70S.
37 Williams LJ, Mai CT, Edmonds LD, Shaw GM, Kirby RS,
Hobbs CA, et al. Prevalence of spina bifida and anencephaly
during the transition to mandatory folic acid fortification in
the United States. Teratology. 2002;66:33–9.
608-613 Poretti 12352.qxp  8.10.2008  7:52 Uhr  Seite 613
